AstraZeneca launches next-generation PARP inhibitors to continue Lynparza's success

Compileriver

AstraZeneca’s PARP inhibitor Lynparza has quickly become a hot-selling product by inhibiting the full healing ability of tumor cells and killing tumor cells.

At the AACR meeting, AstraZeneca announced early data on its PARP1 selective next-generation inhibitor AZD5305, hoping to emphasize the drug's follow-up and improvement opportunities for the blockbuster Lynparza.

In a set of abstracts, AstraZeneca listed the case of AZD5305, which entered phase I clinical trials in December last year, including early in vivo preclinical data as a single-agent treatment and in combination with standard treatments.

Lynparza is a PARP1/2 inhibitor, and its combined treatment range is limited due to side effects.

The DDR pathway is an ancient target for pharmaceutical manufacturers, but with the advent of PARP, it has become popular and may suppress its frustrating safety features.

Susan Galbraith, Senior Vice President and Head of Oncology Research and Development of AstraZeneca, said: “We believe this will represent cleaner safety features, stronger cell killing power and broader binding capacity in the clinic.

Article reference source:

AstraZeneca unveils next-gen PARP inhibitor, looking to follow up on success of first-gen success story Lynparza